On August 25, 2023, Camac Partners, LLC and ATG Capital Management, LLC announced that they have filed a definitive proxy statement with the U.S. Securities and Exchange Commission in connection with Forte Biosciences, Inc.?s 2023 annual meeting of stockholders scheduled for September 19, 2023. In the letter, Camac Partners and ATG Capital Management highlight destruction of nearly 95% in stockholder value under Chairman and CEO Paul Wagner?s leadership. Camac Partners and ATG Capital Management stated that they expose the Company?s worst-in-class governance and repeated attempts to use corporate machinery as an entrenchment tactic, including most recent private placement, adoption of a low-trigger poison pill and violation of SEC rules in setting record date for upcoming annual meeting.

Camac Partners and ATG Capital Management added that they encourage stockholders to vote for independent director candidates committed to acting in stockholders? best interests ? Michael Hacke and Chris Mcintyre ?

on Camac Partners and ATG Capital Management?s proxy card at the Company?s upcoming annual meeting.